Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1α, HIF-2α, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway

Cancer Research

Volumn 61, Issue 19, 2001, Pages 7349-7355

  Blancher, Christine ^a   Moore, John W ^a   Robertson, Naomi ^a   Harris, Adrian L ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CELL PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; GENE INDUCTION; GENE MUTATION; HUMAN; HUMAN CELL; HYPOXIA; KIDNEY CARCINOMA; ONCOGENE; PRIORITY JOURNAL; PROTEIN INDUCTION; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, RENAL CELL; CELL HYPOXIA; CHROMONES; DNA-BINDING PROTEINS; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; LIGASES; LYMPHOKINES; MORPHOLINES; MUTATION; NUCLEAR PROTEINS; PHOSPHORIC MONOESTER HYDROLASES; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0035477438     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Activation of vascular endothelial growth-factor gene-transcription by hypoxia-inducible factor-1
2. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences
3. Induction of vascular endothelial growth-factor by hypoxia is modulated by a phosphatidylinositol 3-kinase akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-I transcriptional element
4. Oncogenes and tumor angiogenesis: Differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts
5. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes
6. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia
7. Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene
8. Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements
9. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: Implications for tumor angiogenesis
10. Regulation of vascular endothelial growth-factor (vegf) expression is mediated by internal initiation of translation and alternative initiation of transcription
11. Differential expression of vascular endothelial growth factor mRNA versus protein isoform expression in human breast cancer and relationship to eIF-4E
12. Translation of vascular endothelial growth-factor messenger-RNA by internal ribosome entry: Implications for translation under hypoxia
13. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression
14. Function and regulation of ras
15. Oxygen(es) and the hypoxia-inducible factor-I
16. The molecular-basis of the hypoxia response pathway: Tumor hypoxia as a therapy target
17. Regulation of mammalian O-2 homeostasis by hypoxia- inducible factor 1
18. Hypoxia-inducible factor 1-α (hif-1-α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes
19. Regulation of hypoxia-inducible factor 1-α is mediated by an O-2-dependent degradation domain via the ubiquitin-proteasome pathway
20. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
21. Hypoxia-inducible factor 1 α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations
22. V-src induces expression of hypoxia-inducible-factor-1 (hif-1) and transcription of genes encoding vascular endothelial growth-factor and enolase-1 involvement of hif-1 in tumor progression
23. Reciprocal positive regulation of hypoxia-inducible factor 1 α and insulin-like growth factor 2
24. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1 α (HIF-1 α) and enhance the transcriptional activity of HIF-1
25. Cellular survival: A play in three Akts
26. Overexpression of the c-erbB-2 protein in human breast tumor cell lines
27. The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231
28. Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture
29. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines
30. Induction of endothelial pas domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1-α
31. Construction and characterization of a conditionally active version of the serine/threonine kinase Akt
32. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins
33. Improved RNase protection assay for quantifying LDL-receptor mRNA; estimation of analytical imprecision and biological variance in peripheral blood mononuclear cells
34. Quantitative measurement of mRNA using the RNase protection assay
35. Hypoxia inducible factor-α binding and ubiquitylation by the Von Hippel-Lindau tumor suppressor protein
36. EPAS1 trans-activation during hypoxia requires p42/p44 MAPK
37. Modulation of hypoxia-inducible factor 1 expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics
38. Loss of PTEN facilitates HIF-1-mediated gene expression
39. Relation of HIF-1a and HIF-2a expression to VEGF induction and hypoxia survival in human breast cancer cell lines
40. Ras signaling and apoptosis
41. Organization and regulation of mitogen-activated protein kinase signaling pathways
42. Phosphatidylinositol-3-OH kinase as a direct target of Ras
43. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras
44. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein
45. Competitive and noncompetitive inhibition of the DNA-dependent protein kinase
46. A redox mechanism controls differential DNA binding activities of hypoxia-inducible factor (HIF) 1α and the HIF-like factor
47. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia